Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024. "Our lead CAR T program, ATA3219, is advancing as a promising new therapeutic option for oncolo.
- 05/09/2024
|
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 4,150 restricted stock units of Atara's common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara.
- 05/03/2024
|
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of Atara's common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara.
- 04/05/2024
|
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
- Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.72 per share a year ago.
- 03/28/2024
|
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2023, recent business highlights, and key upcoming milestones for 2024. “We are expanding Atara's proven EBV T-cell platform into allogeneic CAR T thera.
- 03/28/2024
|
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell monotherapy for the treatme.
- 02/29/2024
|
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PST /.
- 02/28/2024
|
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced its recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosu.
- 02/14/2024
|
Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
- Atara Biotherapeutics is a biotech company focused on developing cell therapies for Epstein-Barr virus infection and cancer. Their most advanced product, tab-cel, has shown promising results in treating EBV-associated post-transplant lymphoproliferative disease. The company's financial situation is uncertain, but recent partnerships and potential revenue growth from tab-cel could improve their cash runway.
- 02/05/2024
|
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
- THOUSAND OAKS, Calif. & CASTRES, France--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and Pierre Fabre Laboratories, a global player in oncology and responsible for worldwide commercialization of tabelecleucel (tab-cel® or EBVALLO™), today announced that data from the pivotal Phase 3 ALLEL.
- 01/31/2024
|
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a definitive agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727 shares of its common stock at a purchase price of $0.55 per pre-funded warrant share i.
- 01/08/2024
|
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced Pascal Touchon, President and Chief Executive Officer of Atara, will present the Company's 2023 accomplishments across strategic priorities and key upcoming milestones at the 42nd Annual J.P. Morgan Healthc.
- 01/08/2024
|
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, at 9:45 a.m. PST / 12:45 p.m. EST in San Francisco, Cal.
- 01/04/2024
|
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM). Building on the earlier partnership announced in October 2021 to commercialize tab-ce.
- 12/20/2023
|
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced preclinical data on ATA3431, a next-generation allogeneic CD20/CD19-dual targeted chimeric antigen receptor (CAR) EBV T-cell therapy candidate. Findings support ATA3431 advancement into clinical testing, in.
- 12/11/2023
|
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 27,000 restricted stock units of Atara's common stock to three newly hired employees. These awards were approved by the Compensation Committee of Atara's Board of Directors and granted under the.
- 12/01/2023
|
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced positive new data for tabelecleucel (tab-cel® or EBVALLO™) in patients with relapsed or refractory (r/r) or treatment-naïve Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving.
- 11/29/2023
|
Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why
- Atara's (ATRA) shares fell after a phase II study evaluating its multiple sclerosis therapy did not meet its primary endpoint.
- 11/24/2023
|
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:50 a.m. EST. A live.
- 11/22/2023
|
Penny Stocks To Buy Under $1? 3 For Your Holiday Watch List
- Penny stocks offer investors the chance to get in on the ground floor of small companies with growth potential. They also offer high-volatility trading opportunities daily that can see huge moves of 100% or more.
- 11/22/2023
|
11 Top Penny Stocks To Buy Now According To Insiders
- Ever wonder what signals to look for in the stock market today? Let's talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to watch.
- 11/17/2023
|
5 Penny Stocks To Buy Now According To Insiders
- Penny stocks are often priced under $5 per share. They attract traders seeking big gains.
- 11/15/2023
|
Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity
- Atara Biotherapeutics stock price dropped by 80% following failure of ATA188 in a phase 2 study in multiple sclerosis. This was an excessive reaction by the market in my opinion. ATRA's restructuring, tab-cel deal with Pierre Fabre, and lower future R&D expenses (considering failure of ATA188 and prioritization of ATA3219 and ATA3431) have extended cash runaway beyond Q3 2025. Pierre Fabre will not only take over all costs associated with tab-cel but will also pay ATRA $30M upfront, as well as $100M in regulatory milestone payments through BLA approval.
- 11/13/2023
|
Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript
- Atara Biotherapeutics, Inc. (NASDAQ:ATRA ) Q3 2023 Results Conference Call November 1, 2023 9:00 AM ET Company Participants Alex Chapman - VP, Corporate Communications & IR Dr. Pascal Touchon - President and CEO Eric Hyllengren - CFO Conference Call Participants Salim Syed - Mizuho John Newman - Canaccord Genuity Phil Nadeau - Cowen & Company Jonathan Miller - Evercore ISI Tommie Reerink - Goldman Sachs Operator Good morning, and thank you for standing by. Welcome to Atara Biotherapeutics' Third Quarter 2023 Financial Results Conference Call.
- 11/04/2023
|
Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study
- Atara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product candidate, tab-cel, in the treatment of a rare, deadly and hematologic malignancy.
- 09/21/2023
|
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates
- Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.31 per share a year ago.
- 08/08/2023
|
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
- THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 4:00 p.m. PDT / 7.
- 06/07/2023
|
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates
- Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.87 per share a year ago.
- 05/08/2023
|
3 Stocks to Buy That Could Be the Next Biotech Breakthrough
- In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky.
- 04/16/2023
|
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates
- Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -18.03% and 99.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/08/2023
|
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- THOUSAND OAKS, Calif.--( BUSINESS WIRE )--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PST / 6:45 PM EST at the Westin St. Francis Hotel in San Francisco.
- 01/04/2023
|
3 Under-the-Radar Biotech Stocks to Buy in 2022
- The attraction of all three biotech stocks is their potential.
- 12/24/2022
|
Consider Atara Biotherapeutics As The Tab-Cel Delay Resolves In The U.S.
- Atara Biotherapeutics has complications with the FDA while the EU approach is so much clearer. The MS drug is a value driver if ATRA sorts out issues.
- 12/17/2022
|
Atara Biotherapeutics, Inc. (ATRA) Q3 2022 Earnings Call Transcript
- Atara Biotherapeutics, Inc. (NASDAQ:ATRA ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Eric Hyllengren - Vice President of Investor Relations and Finance Dr. Pascal Touchon - President and Chief Executive Officer Dr. Jakob Dupont - Executive Vice President and Global Head of Research and Development Utpal Koppikar - Chief Financial Officer Dr. AJ Joshi - Chief Medical Officer Conference Call Participants Salim Syed - Mizuho Group John Newman - Canaccord Phil Nadeau - Cowen and Company Kallie Briza - Stifel Jessica Hui - Evercore Operator Good afternoon, everyone. Thank you for standing by, and welcome to the Atara Biotherapeutics Third Quarter 2022 Financial Results Conference Call.
- 11/08/2022
|
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
- Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -5.13% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2022
|
Best Penny Stocks To Buy? 5 Biotech Stocks For Your Watch List This Week
- Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?
- 10/24/2022
|
Stock Market Trends, Penny Stocks in 2022
- Are you using these trends to make money with penny stocks? The post Stock Market Trends, Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/27/2022
|
Penny Stocks To Buy Now? 3 To Watch After NERV Stock Explodes 160%
- Penny stocks to buy or avoid? 3 for your watch list right now.
- 08/24/2022
|
These Are The Ten Best And Worst Performing Small-Cap Stocks In July 2022
- The small-cap Russell 2000 gained over 10% in July, compared to a jump of 9.1% for the S&P 500.
- 08/22/2022
|
Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline
- Atara has two possible regulatory approvals for tab-cel for PTLD; European approval expected Q4 of 2022 and BLA filing for U.S. territory to be updated in next quarter earnings call. Two data readouts of ATA188 for treatment of patients with progressive multiple sclerosis; Phase 1 MRI Data/OLE data Q4 2022 and phase 2 EMBOLD study data expected October 2023.
- 08/17/2022
|
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Tops Revenue Estimates
- Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 65.93% and 483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/08/2022
|
After Plunging 65.7% in 4 Weeks, Here's Why the Trend Might Reverse for Atara Biotherapeutics (ATRA)
- Atara Biotherapeutics (ATRA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 08/02/2022
|
Why Atara Biotherapeutics Stock Is Crashing Today
- Investors were hoping for more from the company's latest clinical update.
- 07/13/2022
|
Mizuho On Atara Biotherapeutics - Distinguish Between Small Numbers And Science Failure
- Atara Biotherapeutics Inc (NASDAQ: ATRA) issued its anticipated interim analysis communication for its ATA188 Phase 2 progressive multiple sclerosis trial. Shares slumped over 50%.
- 07/13/2022
|
Atara Biotherapeutics (ATRA) Moves 17% Higher: Will This Strength Last?
- Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 07/13/2022
|
Atara Biotherapeutics Shares Are Plummeting - Read Why
- Atara Biotherapeutics Inc (NASDAQ: ATRA) completed the planned Interim Analysis of the ATA188 Phase 2 study (EMBOLD) in progressive multiple sclerosis patients. The analysis' primary focus was on expanded disability status scale (EDSS) improvement at six months and overall.
- 07/13/2022
|
Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will disclose its completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis via press release after market close on Tuesday, July 12, 2022. Following the release, the Company will hos
- 07/06/2022
|
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics
- Late last week, Atara Biotherapeutics Inc (NASDAQ: ATRA) announced that Bayer AG (OTC: BAYRY) intends to terminate the exclusive worldwide licensing agreement for Atara's mesothelin-targeted allogeneic and autologous CAR-T assets, ATA3271 and ATA2271. The.
- 05/23/2022
|
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
- Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 11.22% and 11.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
Analysts Estimate Atara Biotherapeutics (ATRA) to Report a Decline in Earnings: What to Look Out for
- Atara Biotherapeutics (ATRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/26/2022
|
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2021 Results - Earnings Call Transcript
- Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2021 Results - Earnings Call Transcript
- 02/28/2022
|
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Lags Revenue Estimates
- Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -60% and 84.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2022
|
Is a Surprise Coming for Atara Biotherapeutics (ATRA) This Earnings Season?
- Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/24/2022
|
Atara Biotherapeutics Shares Fall After Reporting Patient Death In ATA2271 Autologous CAR T Trial
- Memorial Sloan Kettering Cancer Center's (MSK) has notified the FDA of a fatal serious adverse event (SAE) associated with a patient in Phase 1 study of Atara Biotherapeutics Inc's (NASDAQ: ATRA) autologous mesothelin CAR T, ATA2271. MSK has voluntarily paused enrollment of new patients in the study temporarily while additional information regarding the case is gathered and reviewed.
- 02/18/2022
|
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced Pascal Touchon, President and Chief Executive Officer of Atara, will present the Company's 2021 accomplishments across strategic priorities and key upcoming catalysts at the 40th Annual J.P. Morgan He
- 01/10/2022
|
Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer of Atara, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM PST / 5:15 PM E
- 01/05/2022
|
Atara: Inordinate FDA Delays Wrecked This Stock
- Atara has been stagnant because of more than a year's worth of delay caused by the CMC review division at the FDA. I see no immediate end to the process; however, this has nearly nothing to do with the asset's viability as a treatment option for EBV-PTLD.
- 12/13/2021
|
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer of Atara, will participate at three upcoming virtual conferences. Cowen 5th Annual IO Next Summit Fireside chat on Monday, November 15, 2021
- 11/08/2021
|
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2021 Results - Earnings Call Transcript
- Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2021 Results - Earnings Call Transcript
- 11/04/2021
|
How Much Upside is Left in Atara Biotherapeutics (ATRA)? Wall Street Analysts Think 48%
- The consensus price target hints at a 48.3% upside potential for Atara Biotherapeutics (ATRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 11/04/2021
|
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
- Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 2.17% and 1.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/04/2021
|
Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the upcoming first release of efficacy and safety results from its Phase 3 ALLELE study. The pivotal trial is investigating tabelecleucel (tab-cel®) for the treatment of Epstein-Barr virus-positive po
- 11/04/2021
|
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
- SOUTH SAN FRANCISCO, Calif. & CASTRES, France--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive
- 10/04/2021
|
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 104,386 restricted stock units of Atara's common stock to 16 newly hired employees and stock options to purchase an aggregate of 107,813 shares of Atara's common stock to five such newly hired
- 10/01/2021
|
Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced the upcoming full release of new translational data and two-year open-label extension (OLE) clinical data from the study of ATA188 in progressive multiple sclerosis (MS). The findings will be presented as an ePoster at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) taking place virtually October 13-15, 2021. The presentation includes n
- 09/29/2021
|
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 74,055 restricted stock units of Atara's common stock to 16 newly hired employees and stock options to purchase an aggregate of 59,869 shares of Atara's common stock to five such newly hired e
- 09/03/2021
|
Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a panel discussion titled, “Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy,” at the Citi 16th
- 09/02/2021
|
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2021 Results - Earnings Call Transcript
- Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
- Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -3.41% and -38.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2021
|
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 110,626 restricted stock units of Atara's common stock to 28 newly hired employees and stock options to purchase an aggregate of 69,744 shares of Atara's common stock to 8 such newly hired empl
- 08/02/2021
|
Atara Biotherapeutics: Upcoming Catalysts And Validated Pipeline
- ATRA will have an approval next year in a rare disease. Its major deal with Bayer validates its earliest stage programs.
- 06/30/2021
|
Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced a combined long-term overall survival (OS) analysis from three clinical studies of tabelecleucel (tab-cel®) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after solid o
- 06/07/2021
|
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 140,861 restricted stock units of Atara's common stock to 28 newly hired employees and stock options to purchase an aggregate of 124,966 shares of Atara's common stock to 7 such newly hired em
- 06/04/2021
|
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of inducement awards to Cokey Nguyen, its Senior Vice President, Chief Scientific Officer. The compensation committee of Atara's board of directors granted Dr
- 05/14/2021
|
Atara Biotherapeutics' (ATRA) CEO Pascal Touchon on Q1 2021 Results - Earnings Call Transcript
- Atara Biotherapeutics' (ATRA) CEO Pascal Touchon on Q1 2021 Results - Earnings Call Transcript
- 05/05/2021
|
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates
- Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/04/2021
|
Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the Company will release first quarter 2021 financial results after market close on Tuesday, May 4, 2021. Following the release, the Company will host a live conferen
- 04/27/2021
|
7 Stocks That Could Double by Summer
- These seven stocks may be risky, but they also have the potential for big returns -- as all of them are stocks that could double by summer. The post 7 Stocks That Could Double by Summer appeared first on InvestorPlace.
- 04/05/2021
|
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of an aggregate of 52,019 restricted stock units of Atara's common stock to 24 newly hired employees and stock options to purchase an aggregate of 82,342 shar
- 04/02/2021
|
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced a combined long-term overall survival (OS) analysis from three clinical studies of tabelecleucel (tab-cel®) in patients with Epstein-Barr virus-driven post-transplant
- 03/14/2021
|
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of restricted stock units to acquire 40,800 shares of common stock to ten newly hired employees and stock options to purchase an aggregate of 55,000 shares of
- 03/05/2021
|
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2020 Results - Earnings Call Transcript
- Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2020 Results - Earnings Call Transcript
- 03/01/2021
|
NexImmune Proposes Terms For $75 Million IPO
- NexImmune Proposes Terms For $75 Million IPO
- 02/08/2021
|
Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the Company will present data in the form of six poster presentations at the Transplantation & Cellular Therapy (TCT) Meeting of the American Society for Transpla
- 01/19/2021
|
Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced President and Chief Executive Officer Pascal Touchon will present Atara's 2020 progress and key upcoming milestones across the Company's strategic prior
- 01/10/2021
|
Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13 at 1:30 PM PST
- 01/06/2021
|
Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today noted that it has not yet initiated the Biologics License Application (BLA) submission for tab-cel® (tabelecleucel), currently in Phase 3 development for Epstein-B
- 01/04/2021
|
Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,102,041 shares of its common stock at a price to the public of $24.50 per share and, to certain investors, pre-fun
- 12/08/2020
|
Atara Biotherapeutics Announces Proposed Offering of Common Stock
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. In connection with the proposed offering, Atara Biotherapeutics ex
- 12/07/2020
|
Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219, a Next-Generation Allogeneic CD19 CAR T Cell Therapy, at the 62nd American Society of Hematology (ASH) Annual Meeting
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of the first preclinical evaluation of ATA3219, a next-generation, off-the-shelf, allogeneic CAR T-cell therapy targeting CD19, as well as data suppor
- 12/07/2020
|
Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
- WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors. The agreement includes the development candidate ATA3271, an armored allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors such as mali
- 12/06/2020
|
Regenerative Medicines: Universal Cell Therapy Gaining Momentum
- Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 months to further elucidate safety and efficacy.
- 12/01/2020
|
Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will present for the first time 15-month safety and efficacy data from all patients in the two highest dose cohorts of the Phase 1a open-label extension (O
- 11/15/2020
|
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2020 Results - Earnings Call Transcript
- Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2020 Results - Earnings Call Transcript
- 11/10/2020
|
Les bénéfices d'AG Barr au H1 glissent en raison des restrictions liées au COVID-19 | Invezz
- AG Barr a enregistré une charge exceptionnelle de 11,5 millions £ au S1 et a dit que les paiements de dividendes pourraient être rétablis en 2021.
- 09/22/2020
|
De H1 winst van AG Barr daalt vanwege COVID-19 beperkingen | Invezz
- De winst van AG Barr over het eerste halfjaar daalt als gevolg van COVID-19. Het bedrijf zag in H1 £11,5 miljoen aan uitzonderlijke lasten.
- 09/22/2020
|
Las ganancias de A.G. Barr se caen debido a las restricciones de COVID-19 en el primer semestre fiscal | Invezz
- En un anuncio el martes, AG Barr plc (LON: BAG) dijo que su ganancia antes de impuestos en el primer semestre fiscal fue menor en una base anual. La compañía atribuyó la disminución a la pandemia de Coronavirus que afectó sus ventas en el primer semestre. El COVID-19 ha infectado hasta el momento a más de 398 mil personas en el Reino Unido y ha causado más de 41 mil muertes. AG Barr abrió alrededor de un 2% en el mercado de valores el martes. Las acciones de la compañía subieron otro 10% en las próximas horas. Con un máximo
- 09/22/2020
|
Il profitto di AG Barr diminuisce a causa del COVID-19 nel Q1 | Invezz
- La società ha registrato £11,5 milioni di spese eccezionali nel Q1. AG Barr afferma che i pagamenti dei dividendi potrebbero essere ripristinati nel 2021.
- 09/22/2020
|
Week 38 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
- Two sample breakout stocks for Week 38 with better than 10% short-term upside potential. Now up an average +199.7% YTD.
- 09/15/2020
|
Wall Street Breakfast: The Week Ahead
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 09/06/2020
|
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 09/05/2020
|
Tracking Seth Klarman's Baupost Group Holdings - Q2 2020 Update
- Seth Klarman’s 13F portfolio value increased from $6.77B to $8.01B this quarter. Baupost Group increased Atara Biotherapeutics while dropping Cheniere Energy.
- 08/15/2020
|
Genomic Medicine: Summer 2020 Update
- FDA approvals, new guidance statements, and RMAT requests all show the pace of genomics is accelerating.
- 08/13/2020
|
Did Hedge Funds Make The Right Call On Atara Biotherapeutics Inc (ATRA) ?
- How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- 08/12/2020
|
Cowen & Co. Remains a Buy on Atara Biotherapeutics (ATRA) - Markets
- In a report issued on August 6, Phil Nadeau from Cowen & Co. maintained a Buy rating on Atara Biotherapeutics
- 08/09/2020
|
H.C. Wainwright Keeps a Buy Rating on Atara Biotherapeutics (ATRA) - Markets
- In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Atara Biotherapeutics (ATRA – Research
- 08/06/2020
|
Canaccord Genuity Sticks to Its Buy Rating for Atara Biotherapeutics (ATRA) - Markets
- In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Atara Biotherapeutics (ATRA – Research
- 08/06/2020
|
Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today reported financial results for the second quarter ended June 30, 2020 and recent business highlights.
- 08/05/2020
|
Why Atara Biotherapeutics (ATRA) Might Surprise This Earnings Season
- Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 08/04/2020
|
Noble Energy Announces Second Quarter Results
- Noble Energy, Inc. (NASDAQ: NBL) (“Noble Energy” or the “Company”) today provided second quarter financial and operating results. “Noble Energy's seco
- 08/03/2020
|
Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release second quarter 2020 financial results after market close on Wednesday, August 5, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Company’s financial results and provide a corporate update.
- 07/29/2020
|
The Retiree's Dividend Portfolio - Jane's June Update: Record Dividends During COVID-19
- Jane's retirement accounts generated a total of $2,047.11 of dividend income for June 2020 vs. $1,561.04 of dividend income for June of 2019.
- 07/27/2020
|
IPO Update: AlloVir Proposes Terms For $251 Million IPO
- AlloVir intends to raise $251 million in a U.S. IPO of its common stock.
- 07/26/2020
|
Automotive E-tailing Industry Outlook to 2027 with Profiles of 43 Players Including Advance Auto Parts, Amazon.com, AutoZone and Wal-Mart Stores - ResearchAndMarkets.com
|
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade
- Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 07/21/2020
|
AlloVir Seeks IPO For Anti-Viral Pipeline Development
- AlloVir has filed to raise $100 million in an IPO. The firm is advancing a pipeline of treatments and preventions for various viral diseases, including Covid19.
- 07/16/2020
|
Assessing If The Bulls Can Gain Control In CenturyLink (NYSE:CTL)
- Value and profitability numbers look really attractive in this stock. Cash-flow multiple also looks compelling.
- 07/09/2020
|
Atara Biotherapeutics Inc (NASDAQ:ATRA) Shares Sold by Victory Capital Management Inc.
- Victory Capital Management Inc. lowered its holdings in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 9.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,419 shares of the biotechnology company’s stock after selling 965 shares during the period. Victory Capital Management Inc.’s holdings in […]
- 07/05/2020
|
Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Strong-Buy at BidaskClub
- Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Friday, BidAskClub reports. Several other research analysts have also recently weighed in on ATRA. Citigroup upgraded shares of Atara Biotherapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price objective […]
- 07/03/2020
|
Will Atara Biotherapeutics Continue to Surge Higher?
- As of late, it has definitely been a great time to be an investor of Atara Biotherapeutics
- 07/01/2020
|
2 Biotech Stocks That Could Soar in 2020
- Despite the market volatility throughout this year, there are still good prospects in this sector, especially in small-cap biotechnology stocks. If you have cash waiting to be put to work, you might want to take a look at these biotechnology stocks that are set to dominate in 2020 and beyond. Atara Biotherapeutics (NASDAQ: ATRA) is a hidden gem poised to move higher.
- 07/01/2020
|
Atreca (BCEL) Received its Third Buy in a Row - Markets
- After H.C. Wainwright and Cowen & Co. gave Atreca (NASDAQ: BCEL) a Buy rating last month, the company received another
- 07/01/2020
|
Benzinga's Top Upgrades, Downgrades For June 30, 2020
- Upgrades * For Crocs Inc (NASDAQ: CROX), Loop Capital upgraded the stock from Hold to Buy. In the first quarter, Crocs showed an EPS of $0.22, compared to $0.36 from the year-ago quarter. The stock has a 52-week-high of $43.79 and a 52-week-low of $8.40. Crocs's stock last closed at $35.07 per share. * Cowen & Co. changed the rating for Hologic Inc (NASDAQ: HOLX) from Market Perform to Outperform. Hologic earned $0.57 in the second quarter, compared to $0.58 in the year-ago quarter. The stock has a 52-week-high of $55.96 and a 52-week-low of $26.49. Hologic's stock last closed at $53.33 per share. * Exane BNP Paribas changed the rating for Armstrong World Industries Inc (NYSE: AWI) from Neutral to Outperform. For the first quarter, Armstrong World Indus had an EPS of $1.10, compared to year-ago quarter EPS of $1.10. The stock has a 52-week-high of $111.46 and a 52-week-low of $62.03. Armstrong World Indus's stock last closed at $74.33 per share. * For PPG Industries Inc (NYSE: PPG), BMO Capital upgraded the stock from Market Perform to Outperform. PPG Industries earned $1.19 in the first quarter, compared to $1.38 in the year-ago quarter. The stock has a 52-week-high of $134.36 and a 52-week-low of $69.77. PPG Industries's stock last closed at $103.91 per share. * Keefe, Bruyette & Woods upgraded the stock for Toll Brothers Inc (NYSE: TOL) from Market Perform to Outperform. For the second quarter, Toll Brothers had an EPS of $0.59, compared to year-ago quarter EPS of $0.87. The stock has a 52-week-high of $49.31 and a 52-week-low of $13.28. Toll Brothers's stock last closed at $31.42 per share. Downgrades * New Street downgraded the stock for 58.com Inc (NYSE: WUBA) from Buy to Neutral. 58.com earned $2.09 in the first quarter. The stock has a 52-week-high of $69.89 and a 52-week-low of $37.92. 58.com's stock last closed at $53.72 per share. * For HollyFrontier Corp (NYSE: HFC), Cowen & Co. downgraded the stock from Market Perform to Underperform. In the first quarter, HollyFrontier showed an EPS of $0.53, compared to $0.54 from the year-ago quarter. The stock has a 52-week-high of $58.88 and a 52-week-low of $18.48. HollyFrontier's stock last closed at $28.46 per share. * HC Wainwright & Co. downgraded the stock for BioNTech SE (NASDAQ: BNTX) from Buy to Neutral. BioNTech earned ($0.26) in the first quarter. The stock has a 52-week-high of $105.00 and a 52-week-low of $12.53. BioNTech's stock last closed at $65.80 per share. * Citigroup downgraded the stock for Chegg Inc (NYSE: CHGG) from Buy to Neutral. For the first quarter, Chegg had an EPS of $0.22, compared to year-ago quarter EPS of $0.15. The stock has a 52-week-high of $70.57 and a 52-week-low of $25.89. Chegg's stock last closed at $66.74 per share. * For Energy Recovery Inc (NASDAQ: ERII), B. Riley FBR downgraded the stock from Buy to Neutral. Energy Recovery earned $0.01 in the first quarter, compared to $0.05 in the year-ago quarter. The stock has a 52-week-high of $12.04 and a 52-week-low of $6.11. Energy Recovery's stock last closed at $8.91 per share. * Baird downgraded the stock for Intercept Pharmaceuticals Inc (NASDAQ: ICPT) from Outperform to Neutral. In the first quarter, Intercept Pharmaceuticals showed an EPS of ($2.86), compared to ($3.03) from the year-ago quarter. The stock has a 52-week-high of $125.00 and a 52-week-low of $44.50. Intercept Pharmaceuticals's stock last closed at $46.70 per share. * BTIG downgraded the stock for Okta Inc (NASDAQ: OKTA) from Buy to Neutral. In the first quarter, Okta showed an EPS of ($0.07), compared to ($0.19) from the year-ago quarter. The stock has a 52-week-high of $206.09 and a 52-week-low of $88.66. Okta's stock last closed at $199.84 per share. * For Intercept Pharmaceuticals Inc (NASDAQ: ICPT), Cowen & Co. downgraded the stock from Outperform to Market Perform. Intercept Pharmaceuticals earned ($2.86) in the first quarter, compared to ($3.03) in the year-ago quarter. The stock has a 52-week-high of $125.00 and a 52-week-low of $44.50. Intercept Pharmaceuticals's stock last closed at $46.70 per share. * KeyBanc downgraded the stock for CyrusOne Inc (NASDAQ: CONE) from Overweight to Sector Weight. For the first quarter, CyrusOne had an EPS of $0.97, compared to year-ago quarter EPS of $0.82. The stock has a 52-week-high of $79.73 and a 52-week-low of $43.72. CyrusOne's stock last closed at $74.47 per share. Initiations * Evercore ISI Group initiated coverage on Atara Biotherapeutics Inc (NASDAQ: ATRA) with an Outperform rating. Atara Biotherapeutics earned ($1.20) in the first quarter, compared to ($1.44) in the year-ago quarter. The stock has a 52-week-high of $21.45 and a 52-week-low of $4.52. Atara Biotherapeutics's stock last closed at $13.84 per share. * With a rating of Buy, TD Securities initiated coverage on Plains All American Pipeline LP (NYSE: PAA). The price target is set at $17.00 for Plains All American. For the first quarter, Plains All American had an EPS of $0.55, compared to year-ago quarter EPS of $0.69. The stock has a 52-week-high of $25.26 and a 52-week-low of $3.00. Plains All American's stock last closed at $8.40 per share. * Citigroup initiated coverage on Spotify Technology SA (NYSE: SPOT) with a Neutral rating. The price target for Spotify Technology is set at $270.00. Spotify Technology earned ($0.22) in the first quarter, compared to ($0.90) in the year-ago quarter. The stock has a 52-week-high of $271.71 and a 52-week-low of $109.18. Spotify Technology's stock last closed at $265.20 per share. * For Square Inc (NYSE: SQ), JMP Securities initiated coverage, by setting the current rating at Market Perform. For the first quarter, Square had an EPS of ($0.02), compared to year-ago quarter EPS of $0.11. The stock has a 52-week-high of $107.84 and a 52-week-low of $32.33. Square's stock last closed at $103.67 per share. * With a rating of Buy, DA Davidson initiated coverage on Clorox Co (NYSE: CLX). The price target is set at $256.00 for Clorox. For the third quarter, Clorox had an EPS of $1.89, compared to year-ago quarter EPS of $1.44. The stock has a 52-week-high of $219.38 and a 52-week-low of $144.12. Clorox's stock last closed at $217.53 per share. * With a rating of Market Outperform, JMP Securities initiated coverage on PayPal Holdings Inc (NASDAQ: PYPL). The price target is set at $195.00 for PayPal Holdings. For the first quarter, PayPal Holdings had an EPS of $0.66, compared to year-ago quarter EPS of $0.78. The stock has a 52-week-high of $175.40 and a 52-week-low of $82.07. PayPal Holdings's stock last closed at $168.35 per share. * With a rating of Hold, Loop Capital initiated coverage on Warner Music Group Corp (NASDAQ: WMG). The price target is set at $33.00 for Warner Music Group. The stock has a 52-week-high of $34.76 and a 52-week-low of $26.99. Warner Music Group's stock last closed at $31.43 per share. * With a rating of Hold, Deutsche Bank initiated coverage on ZoomInfo Technologies Inc (NASDAQ: ZI). The price target is set at $50.00 for ZoomInfo Technologies. The stock has a 52-week-high of $64.40 and a 52-week-low of $32.10. ZoomInfo Technologies's stock last closed at $50.72 per share. * KeyBanc initiated coverage on Pluralsight Inc (NASDAQ: PS) with an Overweight rating. The price target for Pluralsight is set at $22.00. In the first quarter, Pluralsight showed an EPS of ($0.09), compared to ($0.07) from the year-ago quarter. The stock has a 52-week-high of $32.40 and a 52-week-low of $6.59. Pluralsight's stock last closed at $17.35 per share. * KeyBanc initiated coverage on Chegg Inc (NYSE: CHGG) with an Overweight rating. The price target for Chegg is set at $80.00. Chegg earned $0.22 in the first quarter, compared to $0.15 in the year-ago quarter. The stock has a 52-week-high of $70.57 and a 52-week-low of $25.89. Chegg's stock last closed at $66.74 per share. * KeyBanc initiated coverage on 2U Inc (NASDAQ: TWOU) with a Sector Weight rating. In the first quarter, 2U showed an EPS of ($0.33), compared to ($0.15) from the year-ago quarter. The stock has a 52-week-high of $40.55 and a 52-week-low of $11.37. 2U's stock last closed at $36.88 per share.See more from Benzinga * Acuity Brands: Q3 Earnings Insights * Conagra Brands: Q4 Earnings Insights * 7 Communication Services Stocks Moving In Tuesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/30/2020
|
Could AAL, OXY, HOG, COTY, CTL – 5 Debt-Laden Stock Portfolio Actually Score Big?
- What’s common between American Airlines, Centurylink, Coty, Occidental Petroleum, and Harley-Davidson? They are all part of our high leverage portfolio where we advise investors to exercise caution. We identified this portfolio of The Leveraged 5: AAL, CTL, COTY, OXY, HOG - with debt being more...
- 06/30/2020
|
Short sellers are letting their Wirecard shorts ride - ValueWalk
- Short sellers have been raking it in on their Wirecard shorts, but most haven't cashed their positions out yet. Analysis from one firm shows
- 06/25/2020
|
Two Sigma Investments LP Sells 159,628 Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA)
- Two Sigma Investments LP decreased its holdings in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 66.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 81,003 shares of the biotechnology company’s stock after selling 159,628 shares during the period. Two […]
- 06/25/2020
|
Atara Biotherapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that the underwriters of its recently closed underwritten offering of 12,633,039 shares of its common stock and pre-funded warrants to purchase 2,866,961 shares of its common stock have exercised in full their option to purchase an additional 2,325,000 shares of common stock at the public offering price less the underwriting discount. The aggregate net proceeds to Atara from the offering, including the shares sold pursuant to the underwriters’ option, after deducting underwriting discounts and commission and estimated offering expenses, were approximately $189.4 million. Pro forma cash, which is comprised of cash, cash equivalents and short-term investments as of March 31, 2020 of $214.6 million along with the aggregate net proceeds of $189.4 million from the offering, totals $404.0 million, and is expected to enable Atara to fund its planned operations into 2022.
- 06/24/2020
|
BNP Paribas Arbitrage SA Buys 21,150 Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA)
- BNP Paribas Arbitrage SA grew its stake in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 330.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,553 shares of the biotechnology company’s stock after purchasing an additional 21,150 shares during the period. BNP Paribas […]
- 06/24/2020
|
Hedge Funds Have Never Been This Bullish On Atara Biotherapeutics Inc (ATRA)
- In this article we will check out the progression of hedge fund sentiment towards Atara Biotherapeutics Inc (NASDAQ:ATRA) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]
- 06/24/2020
|
Atara Biotherapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transforma
- 06/24/2020
|
Is Atara Biotherapeutics (ATRA) Stock a Solid Choice Right Now?
- Atara Biotherapeutics (ATRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 06/23/2020
|
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Atara Biotherapeutics (ATRA) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics
- 06/23/2020
|
Maverick Capital Ltd. Has $44.25 Million Stake in Atara Biotherapeutics Inc (NASDAQ:ATRA)
- Maverick Capital Ltd. increased its holdings in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 4.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,199,897 shares of the biotechnology company’s stock after purchasing an additional 241,466 shares during the quarter. Atara Biotherapeutics makes up about […]
- 06/23/2020
|
Shaker Heights in line for $762,000 to assist with added expenses through pandemic relief fund
- Ohio Gov. Mike DeWine signed the CARES Act statewide distribution into law on Friday (June 19). with Shaker City Council setting up the required Local Coronavirus Fund three days later.
- 06/23/2020
|
Global E-Signature Market (2019 to 2025) - by Component, Deployment Mode, Type, Use-case, Application, Company, Region, Forecast & Opportunities - ResearchAndMarkets.com
|
Wellington Management Group LLP Purchases 1,422,024 Shares of Centurylink Inc (NYSE:CTL)
- Wellington Management Group LLP grew its position in Centurylink Inc (NYSE:CTL) by 599.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,659,091 shares of the technology company’s stock after acquiring an additional 1,422,024 shares during the period. Wellington Management Group LLP owned […]
- 06/21/2020
|
Grant Shapps vows to safeguard wellbeing of crews on detained cruise ships
- Transport secretary intervenes over fate of 1,500 people stranded on five vessels
- 06/20/2020
|
$0.33 Earnings Per Share Expected for Centurylink Inc (NYSE:CTL) This Quarter
- Equities analysts predict that Centurylink Inc (NYSE:CTL) will announce earnings of $0.33 per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Centurylink’s earnings, with the highest EPS estimate coming in at $0.38 and the lowest estimate coming in at $0.28. Centurylink posted earnings per share of $0.34 […]
- 06/20/2020
|
Alliancebernstein L.P. Buys 84,184 Shares of Centurylink Inc (NYSE:CTL)
- Alliancebernstein L.P. lifted its holdings in shares of Centurylink Inc (NYSE:CTL) by 5.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,724,329 shares of the technology company’s stock after acquiring an additional 84,184 shares during the quarter. Alliancebernstein L.P. owned approximately 0.16% of Centurylink […]
- 06/18/2020
|
Cruise and Maritime Voyages in emergency talks after potential loan deal collapses
- CMV scrambles for funding after failing to secure £25m loan from Barclays
- 06/17/2020
|
Orca Bio Emerges as $1 Billion-Plus Biotech With Mystery Backer - BNN Bloomberg
- Orca Bio raised $192 million from Lightspeed Venture Partners and an unnamed investor for its experimental cell therapy platform.
- 06/17/2020
|
Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the first patient has been enrolled in a Phase 1b study of ATA188, an off-the-shelf, allogeneic EBV-specific T-cell immunotherapy, in patients with progressive forms of multiple sclerosis (MS).
- 06/17/2020
|
Cruise firm CMV seeks rescue deal or risks going under
- Cruise firm Cruise and Maritime Voyages (CMV) is in a race against time to secure emergency funding after the coronavirus crisis left it struggling.
- 06/17/2020
|
Atara Biotherapeutics (NASDAQ:ATRA) Now Covered by HC Wainwright
- Stock analysts at HC Wainwright assumed coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a research report issued to clients and investors on Monday, Marketbeat reports. The firm set a “buy” rating and a $25.00 price target on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 137.19% from the […]
- 06/17/2020
|
Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatment
- 06/17/2020
|
Atreca (BCEL) Gets a Buy Rating from Canaccord Genuity - Markets
- Canaccord Genuity analyst John Newman maintained a Buy rating on Atreca (BCEL – Research Report) today and set a price
- 06/16/2020
|
AlphaCrest Capital Management LLC Lowers Position in Centurylink Inc (NYSE:CTL)
- AlphaCrest Capital Management LLC trimmed its holdings in Centurylink Inc (NYSE:CTL) by 49.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,228 shares of the technology company’s stock after selling 23,280 shares during the period. AlphaCrest Capital Management LLC’s holdings in […]
- 06/16/2020
|
African Energy Atlas 2020-2021: Maps, Graphics and Articles Covering All Aspects of the Energy Sector - ResearchAndMarkets.com
|
Benzinga's Top Upgrades, Downgrades For June 15, 2020
- Upgrades * Berenberg changed the rating for Mondelez International Inc (NASDAQ: MDLZ) from Hold to Buy. For the first quarter, Mondelez International had an EPS of $0.69, compared to year-ago quarter EPS of $0.65. The stock has a 52-week-high of $59.96 and a 52-week-low of $41.19. Mondelez International's stock last closed at $50.73 per share. * Evercore ISI Group upgraded the stock for Public Storage (NYSE: PSA) from Underperform to In-Line. Public Storage earned $2.58 in the first quarter, compared to $2.53 in the year-ago quarter. The stock has a 52-week-high of $266.76 and a 52-week-low of $155.37. Public Storage's stock last closed at $196.34 per share. * Loop Capital changed the rating for RH (NYSE: RH) from Hold to Buy. RH earned $1.27 in the first quarter, compared to $1.85 in the year-ago quarter. The stock has a 52-week-high of $265.87 and a 52-week-low of $73.14. RH's stock last closed at $235.97 per share. * For Werner Enterprises Inc (NASDAQ: WERN), UBS upgraded the stock from Neutral to Buy. Werner Enterprises earned $0.40 in the first quarter, compared to $0.52 in the year-ago quarter. The stock has a 52-week-high of $46.95 and a 52-week-low of $28.71. Werner Enterprises's stock last closed at $39.87 per share. * For Apache Corp (NASDAQ: APA), Citigroup upgraded the stock from Neutral to Buy. For the first quarter, Apache had an EPS of ($0.13), compared to year-ago quarter EPS of $0.10. The stock has a 52-week-high of $33.77 and a 52-week-low of $3.80. Apache's stock last closed at $13.77 per share. * B. Riley FBR upgraded the stock for Six Flags Entertainment Corp (NYSE: SIX) from Neutral to Buy. Six Flags Entertainment earned ($1.00) in the first quarter, compared to ($0.82) in the year-ago quarter. The stock has a 52-week-high of $59.52 and a 52-week-low of $8.75. Six Flags Entertainment's stock last closed at $22.74 per share. * For FormFactor Inc (NASDAQ: FORM), Stifel upgraded the stock from Hold to Buy. FormFactor earned $0.33 in the first quarter, compared to $0.20 in the year-ago quarter. The stock has a 52-week-high of $28.58 and a 52-week-low of $14.34. FormFactor's stock last closed at $25.18 per share. * Morgan Stanley changed the rating for AmerisourceBergen Corp (NYSE: ABC) from Equal-Weight to Overweight. For the second quarter, AmerisourceBergen had an EPS of $2.40, compared to year-ago quarter EPS of $2.11. The stock has a 52-week-high of $102.99 and a 52-week-low of $72.06. AmerisourceBergen's stock last closed at $94.90 per share. * Piper Sandler upgraded the stock for Twilio Inc (NYSE: TWLO) from Neutral to Overweight. In the first quarter, Twilio showed an EPS of $0.06, compared to $0.05 from the year-ago quarter. The stock has a 52-week-high of $209.94 and a 52-week-low of $68.06. Twilio's stock last closed at $191.82 per share. * Piper Sandler upgraded the stock for Shopify Inc (NYSE: SHOP) from Neutral to Overweight. In the first quarter, Shopify showed an EPS of $0.19, compared to $0.09 from the year-ago quarter. The stock has a 52-week-high of $844.00 and a 52-week-low of $281.69. Shopify's stock last closed at $742.70 per share. * For Intel Corp (NASDAQ: INTC), KeyBanc upgraded the stock from Sector Weight to Overweight. In the first quarter, Intel showed an EPS of $1.45, compared to $0.89 from the year-ago quarter. The stock has a 52-week-high of $69.29 and a 52-week-low of $43.63. Intel's stock last closed at $59.33 per share. Downgrades * Atlantic Equities changed the rating for Advance Auto Parts Inc (NYSE: AAP) from Neutral to Underweight. For the first quarter, Advance Auto Parts had an EPS of $0.91, compared to year-ago quarter EPS of $2.46. The stock has a 52-week-high of $171.43 and a 52-week-low of $71.33. Advance Auto Parts's stock last closed at $135.81 per share. * For Kimco Realty Corp (NYSE: KIM), Evercore ISI Group downgraded the stock from In-Line to Underperform. Kimco Realty earned $0.37 in the first quarter, compared to $0.37 in the year-ago quarter. The stock has a 52-week-high of $21.86 and a 52-week-low of $7.45. Kimco Realty's stock last closed at $13.76 per share. * Evercore ISI Group downgraded the stock for Macerich Co (NYSE: MAC) from In-Line to Underperform. Macerich earned $0.81 in the first quarter, compared to $0.81 in the year-ago quarter. The stock has a 52-week-high of $35.94 and a 52-week-low of $4.81. Macerich's stock last closed at $9.77 per share. * Clarksons Platou downgraded the stock for Transocean Ltd (NYSE: RIG) from Buy to Neutral. For the first quarter, Transocean had an EPS of ($0.30), compared to year-ago quarter EPS of ($0.30). The stock has a 52-week-high of $7.28 and a 52-week-low of $0.76. Transocean's stock last closed at $2.20 per share. * Evercore ISI Group changed the rating for Ventas Inc (NYSE: VTR) from In-Line to Underperform. For the first quarter, Ventas had an EPS of $0.97, compared to year-ago quarter EPS of $0.99. The stock has a 52-week-high of $75.40 and a 52-week-low of $13.35. Ventas's stock last closed at $39.41 per share. Initiations * With a rating of Buy, HC Wainwright & Co. initiated coverage on Atara Biotherapeutics Inc (NASDAQ: ATRA). The price target is set at $25.00 for Atara Biotherapeutics. In the first quarter, Atara Biotherapeutics showed an EPS of ($1.20), compared to ($1.44) from the year-ago quarter. The stock has a 52-week-high of $22.59 and a 52-week-low of $4.52. Atara Biotherapeutics's stock last closed at $9.38 per share. * With a rating of Buy, Seaport Global initiated coverage on Edison International (NYSE: EIX). The price target is set at $70.00 for Edison Intl. Edison Intl earned $0.63 in the first quarter, compared to $0.63 in the year-ago quarter. The stock has a 52-week-high of $78.93 and a 52-week-low of $43.63. Edison Intl's stock last closed at $57.59 per share. * With a rating of Buy, HC Wainwright & Co. initiated coverage on KalVista Pharmaceuticals Inc (NASDAQ: KALV). The price target is set at $30.00 for KalVista Pharmaceuticals. For the third quarter, KalVista Pharmaceuticals had an EPS of ($0.52), compared to year-ago quarter EPS of ($0.23). The stock has a 52-week-high of $23.23 and a 52-week-low of $5.61. KalVista Pharmaceuticals's stock last closed at $10.41 per share. * With a rating of Buy, Seaport Global initiated coverage on Sempra Energy (NYSE: SRE). The price target is set at $142.00 for Sempra Energy. In the first quarter, Sempra Energy showed an EPS of $3.08, compared to $1.92 from the year-ago quarter. The stock has a 52-week-high of $161.87 and a 52-week-low of $88.00. Sempra Energy's stock last closed at $124.06 per share. * With a rating of Neutral, Rosenblatt initiated coverage on Synaptics Inc (NASDAQ: SYNA). The price target is set at $66.00 for Synaptics. For the third quarter, Synaptics had an EPS of $1.49, compared to year-ago quarter EPS of $0.83. The stock has a 52-week-high of $84.75 and a 52-week-low of $27.45. Synaptics's stock last closed at $62.61 per share. * With a rating of Equal-Weight, Morgan Stanley initiated coverage on Theravance Biopharma Inc (NASDAQ: TBPH). The price target is set at $30.00 for Theravance Biopharma. In the first quarter, Theravance Biopharma showed an EPS of ($1.14), compared to ($1.32) from the year-ago quarter. The stock has a 52-week-high of $31.54 and a 52-week-low of $15.35. Theravance Biopharma's stock last closed at $25.25 per share. * Jefferies initiated coverage on Staar Surgical Co (NASDAQ: STAA) with a Buy rating. The price target for Staar Surgical is set at $55.00. In the first quarter, Staar Surgical showed an EPS of $0.04, compared to $0.03 from the year-ago quarter. The stock has a 52-week-high of $44.91 and a 52-week-low of $23.20. Staar Surgical's stock last closed at $42.73 per share. * Citigroup initiated coverage on SelectQuote Inc (NYSE: SLQT) with a Buy rating. The price target for SelectQuote is set at $32.00. The stock has a 52-week-high of $29.00 and a 52-week-low of $25.28. SelectQuote's stock last closed at $27.45 per share. * With a rating of Outperform, RBC Capital initiated coverage on SelectQuote Inc (NYSE: SLQT). The price target is set at $32.00 for SelectQuote. The stock has a 52-week-high of $29.00 and a 52-week-low of $25.28. SelectQuote's stock last closed at $27.45 per share. * With a rating of Overweight, Atlantic Equities initiated coverage on Starbucks Corp (NASDAQ: SBUX). The price target is set at $95.00 for Starbucks. Starbucks earned $0.32 in the second quarter, compared to $0.60 in the year-ago quarter. The stock has a 52-week-high of $99.72 and a 52-week-low of $50.02. Starbucks's stock last closed at $76.38 per share. * With a rating of Equal-Weight, Morgan Stanley initiated coverage on Packaging Corp of America (NYSE: PKG). The price target is set at $93.00 for Packaging Corp of America. Packaging Corp of America earned $1.50 in the first quarter, compared to $1.98 in the year-ago quarter. The stock has a 52-week-high of $114.78 and a 52-week-low of $71.05. Packaging Corp of America's stock last closed at $98.95 per share. * Morgan Stanley initiated coverage on International Paper Co (NYSE: IP) with an Underweight rating. In the first quarter, International Paper showed an EPS of $0.57, compared to $1.11 from the year-ago quarter. The stock has a 52-week-high of $47.64 and a 52-week-low of $26.38. International Paper's stock last closed at $34.92 per share. * Jefferies initiated coverage on Glaukos Corp (NYSE: GKOS) with a Hold rating. The price target for Glaukos is set at $44.00. Glaukos earned ($0.44) in the first quarter, compared to ($0.04) in the year-ago quarter. The stock has a 52-week-high of $84.65 and a 52-week-low of $23.31. Glaukos's stock last closed at $38.65 per share. * Morgan Stanley initiated coverage on EPAM Systems Inc (NYSE: EPAM) with a Equal-Weight rating. The price target for EPAM Systems is set at $246.
- 06/15/2020
|
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (NASDAQ: KALV), Atara Biotherapeutics (NASDAQ: ATRA) and EKSO BIONICS (NASDAQ: EKSO) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on KalVista Pharmaceuticals
- 06/15/2020
|
Prudent Corporate celebrates 20th anniversary in 2020
- Prudent Corporate, one of India’s fastest growing integrated Wealth Management Group has completed 20 years of its journey in May 2020.
- 06/12/2020
|
CenturyLink: More Debt Progress (NYSE:CTL)
- Level 3 Financing subsidiary prices $1.2 billion in new debt. Lower interest, pushed back maturities help the balance sheet. LIBOR rate fall further helps, perh
- 06/11/2020
|
CenturyLink: Free Cash Flow Is King (NYSE:CTL)
- CTL’s primary focus is on driving growth in profitable revenue and free cash flow per share. No revenue growth is expected in 2020. Maintaining or growing FCF i
- 06/08/2020
|
Atara Biotherapeutics Announces its 2020 Annual Meeting of Stockholders Will Be Held on June 16, 2020 in Virtual Format
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that, due to public health and safety concerns related to the coronavirus ("COVID-19") pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees, and others, it will host its 2020 Annual Meeting of Stockholders ("Annual Meeting") as a virtual-only meeting that will be held via live audio webcast. The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting.
- 06/05/2020
|
Atara Biotherapeutics to Participate at Two Upcoming Conferences
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Pascal Touchon, the Company’s President and Chief Executive Officer, will participate at two upcoming virtual conferences in June.
- 06/04/2020
|
Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy
- CAMBRIDGE, Mass., June 4, 2020 /PRNewswire via COMTEX/ --
CAMBRIDGE, Mass., June 4, 2020 /PRNewswire/ -- Artax Biopharma, Inc., a biotechnology company...
- 06/04/2020
|
Adams Resources & Energy: A Bet On Oil And Management (NYSEMKT:AE)
- Crude oil prices are still the primary driver of earnings. Recent acquisitions lead to an increased focus on the transportation segment. New management across t
- 05/31/2020
|
Xconomy: Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem's Approval & More
- A year ago about 40,000 people gathered in Chicago for the annual meeting of the American Society of Clinical Oncology. Today a virtual version of the
- 05/29/2020
|
Love Island doughnut maker expanding into Chesterfield
- They've even whipped up orders for Royalty
- 05/27/2020
|
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
|
Atara Biotherapeutics Prices 12.6M Share Public Offering @$11.32/Share
|
96 Biggest Movers From Yesterday
|
Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering
- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the pricing of an underwritten public offering of 12,633,039 shares of its common stock at a price to the public of $11.32 per share and, to certain investors, pre-funded warrants to purchase 2,866,961 shares of its common stock at a purchase price of $11.3199 per pre-funded warrant share, which represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of each such pre-funded warrant share. The aggregate gross proceeds from the offering are expected to be approximately $175.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Atara Biotherapeutics. The offering is expected to close on or about May 29, 2020, subject to customary closing conditions. In connection with the offering, Atara Biotherapeutics has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
- 05/27/2020
|
Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering
- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transforma
- 05/27/2020
|
Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants; No Terms Disclosed
|
Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of its common stock. The pre-funded warrants will be offered at the same price per share as the common stock, less the $0.0001 per share exercise price of each pre-funded warrant multiplied by the number of shares subject to the warrant. In connection with the proposed offering, Atara Biotherapeutics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total of the number of shares of its common stock plus the number of shares underlying the pre-funded warrants to be sold in the offering at the public offering price, less the underwriting discounts and commissions. All of the shares and pre-funded warrants in the proposed offering will be sold by Atara Biotherapeutics. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
- 05/26/2020
|
61 Stocks Moving In Tuesday's Mid-Day Session
|
Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months With ATA188 In Patients With Progressive Multiple Sclerosis In Late-Breaking e-Poster At 2020 European Academy Of Neurology Virtual Congress
|
Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at the 2020 European Academy of Neurology Virtual Congress
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of additional safety and efficacy data from its ongoing Phase 1 study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS). ATA188 is an off-the-shelf, allogeneic EBV-specific T-cell immunotherapy. These data demonstrate that ATA188 was well-tolerated across all four dose cohorts; there was a higher proportion of patients showing sustained disability improvements with increasing dose, and sustained disability improvements seen at six months were maintained at 12 months in all three cohorts that have reached the 12-month time point in the study. The results are featured in a late-breaking e-poster at the 6th Congress of the European Academy of Neurology (EAN) virtual meeting, held on May 23-26, 2020.
- 05/26/2020
|
Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at the 2020 European Academy of Neurology Virtual Congress
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatment
- 05/26/2020
|
Atara Jumps After Data Released On Multiple Sclerosis Study
|
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 21)
ADC Therapeutics SA (NYSE:...
- 05/22/2020
|
70 Biggest Movers From Yesterday
|
Shares of several healthcare companies are trading higher in sympathy with the overall market amid strength in oil, strong earnings from Lowe's and optimism towards a US economic rebound.
|
Atara Biotherapeutics Highlights Will Present Late-Breaking ATA188 Data In Progressive Multiple Sclerosis At European Academy Of Neurology Virtual Congress
|
Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology (EAN) Virtual Congress
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will present updated safety and efficacy data from its ongoing Phase 1 study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS) in a late-breaking e-poster presentation at the 6th European Academy of Neurology (EAN) Annual Congress, held virtually from Paris, May 23-26, 2020.
- 05/19/2020
|
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of inducement awards to Jakob Dupont, its Executive Vice President, Global Head of Research & Development.
- 05/18/2020
|
Atara Biotherapeutics (ATRA) Moves to Strong Buy: Rationale Behind the Upgrade
- Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- 05/18/2020
|
Atara Biotherapeutics (ATRA) Moves to Strong Buy: Rationale Behind the Upgrade
|
Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that an abstract describing the preclinical safety, improved functional characteristics and antitumor efficacy of ATA2271, a next-generation autologous chimeric antigen receptor (CAR) T cell therapy targeting mesothelin, was selected for a late-breaking poster presentation at the second American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 to be held on June 22-24, 2020.
- 05/15/2020
|
Slate Path Capital LP Buys Mylan NV, Ironwood Pharmaceuticals Inc, Pan American Silver Corp, ...
|
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today named cell therapy and oncology expert Jakob Dupont, M.D. as Executive Vice President, Global Head of Research and Development (R&D;).
- 05/14/2020
|
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transform
- 05/14/2020
|
Why Atara Biotherapeutics (ATRA) Stock Might be a Great Pick
- Atara Biotherapeutics (ATRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 05/13/2020
|
JP Morgan Maintains Neutral on Atara Biotherapeutics, Raises Price Target to $23
|
Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the appointment of immunology and cell & gene therapy expert Maria Grazia Roncarolo, MD, to the Board of Directors.
- 05/11/2020
|
U.S. RESEARCH ROUNDUP-Acushnet Holdings, Equity Residential, Fiserv
- Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Acushnet Holdings, Equity Residential and Fiserv, on
Monday.
HIGHLIGHTS
* Acushnet Holdings Corp : Stephens raises target price to $27 from $24
* Equity Residential : Evercore ISI raises to in-line from underperform
* Fiserv Inc : Keybanc raises target price to $115 from $108
* GTT Communications Inc : SunTrust Robinson cuts to hold from buy
* UDR Inc : Evercore ISI raises to in-line from underperform
Following is a summary of research actions on U.S. companies reported by Reuters on Monday.
Stock entries are in alphabetical order.
* Abbvie Inc : SVB Leerink raises price target to $122 from $107
* Accelerate Diagnostics Inc : Piper Sandler cuts target price to $14 from $16
* Acushnet Holdings Corp : Compass Point raises TP to $22.25 from $21.50
* Acushnet Holdings Corp : Keybanc raises target price to $31 from $28
* Acushnet Holdings Corp : Stephens raises target price to $27 from $24
* Advance Auto Parts Inc : UBS raises target price to $140 from $135
* AIG : UBS cuts target price to $45 from $49
* Air Lease Corp : Deutsche Bank cuts target price to $36 from $45
* Air Lease Corp : Stephens raises target price to $36 from $30
* Airgain Inc : Northland Capital Markets raises target price to $23
* Alarm.Com Holdings Inc : Credit Suisse cuts target price to $62 from $64
* Albemarle Corp : RBC raises target price to $66 from $64
* Albemarle Corp : SunTrust Robinson cuts target price to $65 from $90
* Allegiant Travel Co : Evercore ISI cuts target price to $95 from $100
* Allscripts Healthcare Solutions : Canaccord Genuity cuts TP to $11 from $13
* Amdocs Ltd : Citigroup cuts price target to $76 from $83
* Amedisys Inc : Raymond James cuts price target to $210 from $225
* Amedisys Inc : UBS cuts target price to $190 from $208
* American Axle & Manufacturing Holdings : Citigroup raises TP to $7.5 from $6
* American Axle & Manufacturing Holdings : RBC raises target price to $7 from $5
* American Homes 4 Rent : Evercore ISI raises target price to $27 from $25
* Ameriprise Financial Inc : RBC raises target price to $155 from $145
* Amerisourcebergen Corp : Deutsche Bank raises target price to $98 from $93
* Amphastar Pharmaceuticals Inc : BMO raises price target to $21 from $20
* Angi Homeservices Inc : Citigroup raises price target to $10 from $6.5
* Aon Plc : Citigroup cuts price target to $230 from $240
* Aon Plc : KBW raises target price to $192 from $184
* Aon Plc : UBS cuts target price to $197 from $202
* Apache Corp : CFRA cuts to sell from hold; raises price target to $9
* Apache Corp : MKM Partners cuts target price by $1 to $19
* Aptiv Plc : Benchmark cuts price target to $87 from $90
* Arch Capital Group Ltd : UBS cuts target price to $39 from $43
* Atara Biotherapeutics Inc : Jefferies cuts target price to $11 from $13
* Athene Holding Ltd : BMO cuts price target to $60 from $63
* Atricure Inc : BTIG raises target price to $56 from $45
* Atricure Inc : Needham raises target price to $63 from $49
* Atricure Inc : Oppenheimer raises price target to $52 from $45
* Atricure Inc : SVB Leerink raises price target to $55 from $50
* Autonation Inc : CFRA cuts price target by $10 to $50
* Avalonbay Communities Inc : Evercore ISI cuts target price to $181 from $189
* Avista Corp : Guggenheim cuts target price to $38 from $39
* Bain Capital Specialty Finance : Citigroup raises price target to $10 from $7.5
* Ball Corp : Citigroup cuts price target to $86 from $89
* Ball Corp : Northland Capital Markets cuts target price to $80
* Baudax Bio Inc : Oppenheimer cuts price target to $14 from $16
* Bellring Brands Inc : Stifel cuts target price to $23 from $25
* BJ's Restaurants Inc : Deutsche Bank raises target price to $27 from $26
* Bloomin' Brands Inc : BMO raises price target to $10 from $9
* Bloomin' Brands Inc : Deutsche Bank raises target price to $15 from $14
* Bloomin' Brands Inc : Guggenheim raises target price to $15 from $11
* Bloomin' Brands Inc : Raymond James cuts target price to $14 from $15
* BP Midstream Partners LP : Mizuho raises target price to $14 from $13
* Broadridge Financial Solutions : Piper Sandler cuts TP to $120 from $124
* Broadridge Financial Solutions : Rosenblatt Securities ups TP to $115 from $101
* Brookfield Infrastructure Partners LP : BMO raises price target to $46 from $45
* Brookfield Infrastructure Partners LP : Scotiabank cuts Tp to $50 from $51
* Brookfield Property Partners LP : Canaccord Genuity cuts TP to $12 from $13
* Brookfield Property Partners LP : CIBC cuts target price to $18 from $20.50
* Brookfield Property Partners LP : RBC cuts target price to $18 from $22
* Bruker Corp : BTIG cuts price target to $50 from $57
* Cabot Oil & Gas Corp : Tudor Pickering Holt cuts to hold from buy
* Calithera Biosciences Inc : Citigroup raises price target to $10 from $7
* Callaway Golf Co : >: Compass Point cuts target price to $17.50 from $20
* Callaway Golf Co : Compass Point cuts target price to $17.50 from $20
* Camden Property Trust : Evercore ISI cuts target price to $98 from $102
* Camden Property Trust : Stifel raises target price to $96 from $91
* Cardtronics Plc : D.A. Davidson cuts target price to $34 from $40
* Cardtronics Plc : SunTrust Robinson raises target price to $29 from $23
* Cargurus Inc : RBC raises target price to $25 from $22
* Carnival : HSBC raises to buy from hold; cuts target price to $15.9 from $45.3
* Carrier Global Corp : Citigroup raises price target to $20 from $17
* Carvana Co : Oppenheimer raises price target to $127 from $95
* Carvana Co : Oppenheimer raises target price to $127 from $95
* Casella Waste Systems Inc : Jefferies raises target price to $56 from $52
* Casella Waste Systems Inc : Raymond James raises target price to $56 from $49
* Casella Waste Systems Inc : Stifel raises target price to $47 from $45
* Cellectis : Citigroup cuts price target to $15 from $16
* Centurylink Inc : SunTrust Robinson cuts target price to $9 from $10
* Ceridian Hcm Holding Inc : Jefferies raises target price to $65 from $60
* Chevron Corp : Independent Research raises target price to $98 from $90; hold
* CNX Resources Corp : Tudor Pickering Holt cuts to hold from buy
* Cognizant Technology Solutions : Evercore ISI cuts target price to $53 from $55
* Cognizant Technology Solutions Corp : HSBC cuts target price to $56 from $70
* Coherus Biosciences Inc : Citigroup cuts price target to $30 from $31
* Conagra Brands Inc : SunTrust Robinson cuts to hold from buy
* Consolidated Edison Inc : Evercore ISI cuts target price to $85 from $86
* Continental Resources : TD Securities raises target price to $14.50 from $13.50
* Cooper Tire & Rubber Co : JP Morgan cuts target price to $29 from $30
* Corporate Office Properties Trust : SunTrust Robinson raises TP to $28 from $26
* Corteva Inc : RBC raises target price to $31 from $27
* Covanta Holding : Stifel raises to hold from sell; raises TP to $9.50 from $6.50
* Crocs Inc : Piper Sandler raises target price to $28 from $24
* Cross Country Healthcare Inc : BMO cuts price target to $8 from $11
* Cryoport Inc : Stephens raises target price to $23 from $21
* CVR Energy Inc : Credit Suisse raises target price to $19 from $16
* Cytomx Therapeutics Inc : Wedbush raises target price to $16 from $11
* Danaher Corp : Evercore ISI raises target price to $175 from $150
* Danaher Corp : RBC raises target price to $173 from $159
* Datadog Inc : RBC raises target price to $50 from $43
* Dentsply Sirona : Barrington Research cuts to market perform from outperform
* Dentsply Sirona Inc : UBS cuts target price to $44 from $59
* Dicerna Pharmaceuticals : SunTrust Robinson raises target price to $33 from $28
* Diebold Nixdorf Inc : JP Morgan raises target price to $7 from $6
* Diebold Nixdorf Inc : JP Morgan raises to neutral from underweight
* Discovery Inc : Rosenblatt Securities cuts price target to $24 from $27
* Dish Network Corp : RBC cuts target price to $32 from $39
* Domtar : D.A. Davidson cuts to neutral from buy; cuts TP to $26 from $44
* Domtar Corp : Scotiabank cuts target price to $29 from $30
* Domtar Corp : TD Securities raises target price to $26 from $22
* E. W. Scripps Co : Benchmark cuts target price to $15 from $24
* E. W. Scripps Co : Guggenheim raises target price to $8 from $6.50
* Edison Intl.
- 05/11/2020
|
Will Atara Biotherapeutics Continue to Surge Higher?
- As of late, it has definitely been a great time to be an investor Atara Biotherapeutics
- 05/11/2020
|
Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transform
- 05/11/2020
|
Edited Transcript of ATRA earnings conference call or presentation 6-May-20 8:30pm GMT
- Q1 2020 Atara Biotherapeutics Inc Earnings Call
- 05/08/2020
|
Noble Energy Announces First Quarter Results
- Noble Energy, Inc. (NASDAQ: NBL) (“Noble Energy” or the “Company”) today provided first quarter financial and operating results. First quarter highlig
- 05/08/2020
|
Atara Biotherapeutics Inc (ATRA) Q1 2020 Earnings Call Transcript
- Ladies and gentlemen, thank you for standing by, and welcome to the Atara Biotherapeutics First Quarter 2020 Financial Results Conference Call. Thank you, Eric, and thanks to all of you for joining us this afternoon.
- 05/07/2020
|
Edited Transcript of ATRA earnings conference call or presentation 6-May-20 8:30pm GMT
- Q1 2020 Atara Biotherapeutics Inc Earnings Call
- 05/07/2020
|
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q1 2020 Results - Earnings Call Transcript
- Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q1 2020 Results Conference Call May 06, 2020 04:30 PM ET Company Participants Eric Hyllengren - Vice President of Inve
- 05/07/2020
|
Atara Biotherapeutics Announces First Quarter 2020 Financial Results and Operational Progress
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today reported financial results for the first quarter ended March 31, 2020 and recent business highlights.
- 05/06/2020
|
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
- 05/06/2020
|
Reviewing Neon Therapeutics (NASDAQ:NTGN) & Atara Biotherapeutics (NASDAQ:ATRA)
- Neon Therapeutics (NASDAQ:NTGN) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership. Analyst Ratings This is a breakdown of recent ratings and target prices for Neon Therapeutics […]
- 05/02/2020
|
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Dynavax (DVAX)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN) and Dynavax (DVAX) with
- 05/01/2020
|
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Dynavax (NASDAQ: DVAX)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (
BMRN
–
Research Report
) and Dynavax (
DVAX
–
Research Report
) with bullish sentiments.
BioMarin Pharmaceutical (BMRN)
William B
- 05/01/2020
|
Kiadis Pharma (KIADF) Receives a Buy from Canaccord Genuity
- Canaccord Genuity analyst John Newman maintained a Buy rating on Kiadis Pharma (KIADF) yesterday and set a price target of EUR4.00. The company's shares
- 05/01/2020
|
Kiadis Pharma (KIADF) Receives a Buy from Canaccord Genuity
- Canaccord Genuity analyst
John Newman
maintained a
Buy
rating on Kiadis Pharma (
KIADF
–
Research Report
) yesterday and set a price target of
EUR4.00
. The company’s shares closed last Monday at $1.97, close to its 52-week low of $1.50.
According to
- 05/01/2020
|
Agios Pharma (AGIO) Gets a Buy Rating from Canaccord Genuity
- In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Agios Pharma (AGIO), with a price target of $72.00. The
- 05/01/2020
|
Agios Pharma (AGIO) Gets a Buy Rating from Canaccord Genuity
- In a report released yesterday,
John Newman
from Canaccord Genuity maintained a
Buy
rating on Agios Pharma (
AGIO
–
Research Report
), with a price target of
$72.00
. The company’s shares closed last Thursday at $41.14.
According to
TipRanks.com
, Ne
- 05/01/2020
|
Mizuho Securities Reaffirms Their Hold Rating on Amgen (AMGN)
- In a report released today, Salim Syed from Mizuho Securities reiterated a Hold rating on Amgen (AMGN), with a price target of $215.00. The company's
- 04/30/2020
|
Mizuho Securities Reaffirms Their Hold Rating on Amgen (AMGN)
- In a report released today, Salim Syed from Mizuho Securities reiterated a Hold rating on Amgen (AMGN – Research Report),
- 04/30/2020
|
Atara Biotherapeutics to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the Company will release first quarter 2020 financial results after market close on Wednesday, May 6, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Company’s financial results and provide a corporate update.
- 04/30/2020
|
Atara Biotherapeutics Appoints Biotech and Finance Industry Veteran Ron Renaud as Non-Executive Chair of the Board of Directors
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the appointment of biotech and finance industry veteran Ron Renaud as a director and non-executive
- 04/30/2020
|
Atreca (BCEL) Receives a Buy from Canaccord Genuity
- Canaccord Genuity analyst John Newman maintained a Buy rating on Atreca (BCEL) yesterday and set a price target of $23.00. The company's shares closed
- 04/30/2020
|
Atreca (BCEL) Receives a Buy from Canaccord Genuity
- Canaccord Genuity analyst John Newman maintained a Buy rating on Atreca (BCEL – Research Report) yesterday and set a price
- 04/30/2020
|
Allogene Therapeutics (ALLO) Gets a Buy Rating from Canaccord Genuity
- In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Allogene Therapeutics (ALLO), with a price target of $36.00.
- 04/30/2020
|
Allogene Therapeutics (ALLO) Gets a Buy Rating from Canaccord Genuity
- In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Allogene Therapeutics (ALLO – Research
- 04/30/2020
|
Mizuho Securities Sticks to Their Buy Rating for Gilead Sciences (GILD)
- In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Gilead Sciences (GILD), with a price target of $81.00. The
- 04/29/2020
|
Mizuho Securities Sticks to Their Buy Rating for Gilead Sciences (GILD)
- In a report released today,
Salim Syed
from Mizuho Securities maintained a
Buy
rating on Gilead Sciences (
GILD
–
Research Report
), with a price target of
$81.00
. The company’s shares closed last Wednesday at $80.50.
According to
TipRanks.com
, Sye
- 04/29/2020
|
Canaccord Genuity Remains a Buy on Aptose Biosciences (APTO)
- Canaccord Genuity analyst John Newman maintained a Buy rating on Aptose Biosciences (APTO) yesterday and set a price target of $13.00. The company's
- 04/28/2020
|
Canaccord Genuity Believes Regeneron (REGN) Still Has Room to Grow
- In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Regeneron (REGN), with a price target of $575.00. The
- 04/28/2020
|
Contrasting Atara Biotherapeutics (NASDAQ:ATRA) & Acorda Therapeutics (NASDAQ:ACOR)
- Atara Biotherapeutics (NASDAQ:ATRA) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership. Earnings & Valuation This table compares Atara Biotherapeutics and Acorda Therapeutics’ revenue, earnings per share […]
- 04/28/2020
|
7 Disruptive Biotech Stocks to Buy for 2025
- RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.
- 04/27/2020
|
2 Top Biotech Stocks Under $10
- Amarin and Atara Biotherapeutics could both be diamonds in the rough.
- 04/27/2020
|
William Blair Remains a Buy on Aileron Therapeutics (ALRN)
- William Blair analyst Matt Phipps maintained a Buy rating on Aileron Therapeutics (ALRN) on April 22. The company's shares closed last Friday at $0.53.
- 04/24/2020
|
William Blair Remains a Buy on Aileron Therapeutics (ALRN)
- William Blair analyst
Matt Phipps
maintained a
Buy
rating on Aileron Therapeutics (
ALRN
–
Research Report
) on April 22. The company’s shares closed last Friday at $0.53.
According to
TipRanks.com
, Phipps has currently no stars on a ranking scale o
- 04/24/2020
|
William Blair Remains a Buy on Incyte (INCY)
- In a report issued on April 20, Matt Phipps from William Blair maintained a Buy rating on Incyte (INCY). The company's shares closed last Friday at
- 04/24/2020
|
William Blair Remains a Buy on Incyte (INCY)
- In a report issued on April 20, Matt Phipps from William Blair maintained a Buy rating on Incyte (INCY –
- 04/24/2020
|
Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Zogenix (ZGNX)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB) and Zogenix (ZGNX). Biogen (BIIB) In a report issued on
- 04/24/2020
|
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (NASDAQ: BIIB) and Zogenix (NASDAQ: ZGNX)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (
BIIB
–
Research Report
) and Zogenix (
ZGNX
–
Research Report
).
Biogen (BIIB)
In a report issued on April 22,
Matt Phipps
from William Blair reiterated a
Hold
- 04/24/2020
|
Gilead Sciences (GILD) Receives a Buy from Mizuho Securities
- Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILD) today and set a price target of $81.00. The company's shares closed
- 04/23/2020
|
Gilead Sciences (GILD) Receives a Buy from Mizuho Securities
- Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a
- 04/23/2020
|
Two shops cut views on Biogen as hopes for Alzheimer's med fade
- Athersys (NASDAQ:ATHX) initiated with an Outperform rating and a $14 (528% upside) price target at SMBC Nikko.Livongo Health (NASDAQ:LVGO) initiated with a Buy rating and a $46 (22% upside) price targ
- 04/23/2020
|
Atara Biotherapeutics upgraded to Buy on valuation at Citi ATRA
- Atara Biotherapeutics upgraded to Buy on valuation at Citi Citi ATRA
- 04/23/2020
|
Analysts Offer Insights on Healthcare Companies: Tactile Systems Technology (TCMD) and Aileron Therapeutics (ALRN)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tactile Systems Technology (TCMD) and Aileron Therapeutics
- 04/23/2020
|
Analysts Offer Insights on Healthcare Companies: Tactile Systems Technology (NASDAQ: TCMD) and Aileron Therapeutics (NASDAQ: ALRN)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tactile Systems Technology (
TCMD
–
Research Report
) and Aileron Therapeutics (
ALRN
–
Research Report
) with bullish sentiments.
Tactile Systems Technolo
- 04/23/2020
|
Atara Biotherapeutics upgraded to Buy from Neutral at Citi ATRA
- Atara Biotherapeutics upgraded to Buy from Neutral at Citi Citi ATRA
- 04/23/2020
|
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to Amar Murugan, its Senior Vice President, General Counsel.
- 04/23/2020
|
Atara Biotherapeutics shares are trading higher after Citigroup upgraded the stock from Neutral to Buy.
|
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Medtronic (MDT)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB) and Medtronic (MDT). Biogen (BIIB) Mizuho Securities
- 04/22/2020
|
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Medtronic (NYSE: MDT)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (
BIIB
–
Research Report
) and Medtronic (
MDT
–
Research Report
).
Biogen (BIIB)
Mizuho Securities analyst
Salim Syed
maintained a
Hold
rating on Biogen today a
- 04/22/2020
|
Atara Biotherapeutics Inc (NASDAQ:ATRA) Stake Lessened by Bank of America Corp DE
- Bank of America Corp DE cut its stake in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 28.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,386 shares of the biotechnology company’s stock after selling 36,859 shares during the period. Bank of America […]
- 04/22/2020
|
These are the best Chromebooks for students of any age!
- In the market for an education-focused Chromebook? These are our favorite ones!
- 04/20/2020
|
Norges Bank Makes New $16.53 Million Investment in Atara Biotherapeutics Inc (NASDAQ:ATRA)
- Norges Bank bought a new position in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,003,746 shares of the biotechnology company’s stock, valued at approximately $16,532,000. Norges Bank owned 1.71% of Atara Biotherapeutics at the […]
- 04/20/2020
|
Geode Capital Management LLC Acquires 36,955 Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA)
- Geode Capital Management LLC lifted its holdings in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 5.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 733,447 shares of the biotechnology company’s stock after purchasing an additional 36,955 shares during the period. Geode Capital Management LLC’s holdings in Atara […]
- 04/20/2020
|
Atara Biotherapeutics (NASDAQ:ATRA) Stock Price Down 2.5%
- Atara Biotherapeutics Inc (NASDAQ:ATRA)’s share price fell 2.5% during trading on Thursday . The company traded as low as $7.64 and last traded at $7.72, 29,474 shares changed hands during mid-day trading. A decline of 96% from the average session volume of 834,763 shares. The stock had previously closed at $7.92. A number of research […]
- 04/18/2020
|
Zacks: Brokerages Anticipate Atara Biotherapeutics Inc (NASDAQ:ATRA) to Announce -$1.36 Earnings Per Share
- Wall Street analysts predict that Atara Biotherapeutics Inc (NASDAQ:ATRA) will announce earnings of ($1.36) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings, with estimates ranging from ($1.60) to ($1.15). Atara Biotherapeutics posted earnings per share of ($1.44) during the same quarter last […]
- 04/18/2020
|
Analysts Offer Insights on Healthcare Companies: Pfenex (PFNX) and Autolus Therapeutics (AUTL)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pfenex (PFNX) and Autolus Therapeutics (AUTL) with bullish
- 04/17/2020
|
Analysts Offer Insights on Healthcare Companies: Pfenex (NYSE MKT: PFNX) and Autolus Therapeutics (NASDAQ: AUTL)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pfenex (PFNX
- 04/17/2020
|
Mizuho Securities Remains a Buy on Gilead Sciences (GILD)
- Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILD) today and set a price target of $81.00. The company's shares closed
- 04/17/2020
|
Mizuho Securities Remains a Buy on Gilead Sciences (GILD)
- Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a
- 04/17/2020
|
Canaccord Genuity Thinks Atara Biotherapeutics' Stock is Going to Recover
- Canaccord Genuity analyst John Newman reiterated a Buy rating on Atara Biotherapeutics (ATRA) today and set a price target of $70.00. The company's shares
- 04/17/2020
|
Canaccord Genuity Thinks Atara Biotherapeutics’ Stock is Going to Recover
- Canaccord Genuity analyst John Newman reiterated a Buy rating on Atara Biotherapeutics (ATRA – Research Report) today and set a
- 04/17/2020
|
Renewal date of health, motor insurance policies further extended to May 15
- If your current health, motor insurance policy is expiring between March 25, 2020 and May 3, 2020 and you are not able to renew your policy because of the country-wide lockdown, then you can renew such health, motor insurance policy by May 15, 2020.
- 04/16/2020
|
Seth Klarman Dials Down Akebia Therapeutics Stake
- Renowned guru slims position in biotech company that focuses on kidney disease Continue reading...
- 04/14/2020
|
Seth Klarman Dials Down Akebia Therapeutics Stake
- Seth Klarman Dials Down Akebia Therapeutics Stake, Stocks: AKBA,TBPH,TBIO,ATRA,GOSS,PRTK, Seth Klarman, release date:Apr 14, 2020
- 04/14/2020
|
Atara Biotherapeutics: Still Bullish On Long-Term Prospects
- Atara Biotherapeutics recently updated that its lead program, tab-cel, remains on track despite the COVID-19 pandemic. Tab-cel is the most advanced allogeneic T
- 04/14/2020
|
Seth Klarman Dials Down Akebia Therapeutics Stake
|
Analysts' Top Healthcare Picks: VBI Vaccines (VBIV), Irhythm Technologies (IRTC)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on VBI Vaccines (VBIV) and Irhythm Technologies (IRTC) with
- 04/13/2020
|
Analysts’ Top Healthcare Picks: VBI Vaccines (VBIV), Irhythm Technologies (IRTC)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on VBI Vaccines
- 04/13/2020
|
Atara Biotherapeutics Inc (NASDAQ:ATRA) Position Reduced by UBS Asset Management Americas Inc.
- UBS Asset Management Americas Inc. trimmed its position in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 87.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,009 shares of the biotechnology company’s stock after selling 312,841 shares during the period. UBS Asset Management Americas Inc. owned […]
- 04/12/2020
|
Atara Biotherapeutics (NASDAQ:ATRA) Trading Up 10.2%
- Atara Biotherapeutics Inc (NASDAQ:ATRA)’s share price was up 10.2% during trading on Thursday . The company traded as high as $8.81 and last traded at $8.55, approximately 1,449,300 shares were traded during trading. An increase of 105% from the average daily volume of 707,820 shares. The stock had previously closed at $7.76. A number of […]
- 04/11/2020
|
Beth Seidenberg
- Beth Seidenberg, founding managing director of Westlake Village BioPartners, is one of Barron’s 100 Most Influential Women in U.S. Finance in 2020. Read more about her career and accomplishments here.
- 04/10/2020
|
Beth Seidenberg
- Beth Seidenberg, founding managing director of Westlake Village BioPartners, is one of Barron’s 100 Most Influential Women in U.S. Finance in 2020. Read more about her career and accomplishments here.
- 04/10/2020
|
Reviewing Idera Pharmaceuticals (NASDAQ:IDRA) and Atara Biotherapeutics (NASDAQ:ATRA)
- Idera Pharmaceuticals (NASDAQ:IDRA) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings. Earnings and Valuation This table compares Idera Pharmaceuticals and Atara Biotherapeutics’ top-line revenue, earnings per […]
- 04/10/2020
|
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SAGE Therapeutics (SAGE) and Pfenex (PFNX)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Incyte (INCY), SAGE Therapeutics (SAGE) and Pfenex (PFNX)
- 04/09/2020
|
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), SAGE Therapeutics (NASDAQ: SAGE) and Pfenex (NYSE MKT: PFNX)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Incyte (
INCY
–
Research Report
), SAGE Therapeutics (
SAGE
–
Research Report
) and Pfenex (
PFNX
–
Research Report
) with bullish sentiments.
Incyte (INCY
- 04/09/2020
|
56 Stocks Moving In Tuesday's Mid-Day Session
- Gainers
Borr Drilling, Inc. (NYSE: BORR) shares jumped 70.9% to $1.3499 after surging over 37% on Monday.
Sasol Limited (NYSE: SSL) shares surged 63.4% to $4.15 amid hopes of...
- 04/07/2020
|
Goldman Sachs Group Inc. Acquires 20,589 Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA)
- Goldman Sachs Group Inc. grew its holdings in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 5.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 422,532 shares of the biotechnology company’s stock after buying an additional 20,589 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Atara Biotherapeutics were worth $6,959,000 as of its most recent […]
- 04/07/2020
|
Assembly Biosciences (ASMB) Receives a Buy from Mizuho Securities
- In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Assembly Biosciences (ASMB), with a price target of $30.00. The
- 04/06/2020
|
Assembly Biosciences (ASMB) Receives a Buy from Mizuho Securities
- In a report released today,
Salim Syed
from Mizuho Securities maintained a
Buy
rating on Assembly Biosciences (
ASMB
–
Research Report
), with a price target of
$30.00
. The company’s shares closed last Monday at $16.62.
According to
TipRanks.com
, S
- 04/06/2020
|
eGenesis Appoints David A. Carmel as Senior Vice President, Public Affairs and Communications
- NEW YORK & CAMBRIDGE, Mass., April 06, 2020 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of safe and effective human-compatible organs to address the global organ shortage, announced that David A. Carmel has been appointed
- 04/06/2020
|
Victory Capital Management Inc. Boosts Stock Position in Atara Biotherapeutics Inc (NASDAQ:ATRA)
- Victory Capital Management Inc. increased its stake in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 31.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,384 shares of the biotechnology company’s stock after purchasing an additional 2,473 shares during the […]
- 04/06/2020
|
Canaccord Genuity Thinks Aileron Therapeutics' Stock is Going to Recover
- Aileron Therapeutics (ALRN) received a Buy rating and a $5.00 price target from Canaccord Genuity analyst John Newman yesterday. The company's shares
- 04/03/2020
|
Canaccord Genuity Thinks Aileron Therapeutics’ Stock is Going to Recover
- Aileron Therapeutics (ALRN – Research Report) received a Buy rating and a $5.00 price target from Canaccord Genuity analyst John
- 04/03/2020
|
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA), Misonix (MSON) and BioNTech SE (BNTX)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Atara Biotherapeutics (ATRA), Misonix (MSON) and BioNTech
- 04/03/2020
|
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (NASDAQ: ATRA), Misonix (NASDAQ: MSON) and BioNTech SE (NASDAQ: BNTX)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Atara Biotherapeutics
- 04/03/2020
|
